l-Arginine l-lysine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: l-Arginine l-lysine
• 英文别名: (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid;(2S)-2,6-diaminohexanoic acid
• 化学式: C12H28N6O4
• 分子量: 320.39
• InChiKey: OGDDUPYYEQZVHV-KDDYFZQKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.02
• 重原子数：
  22
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  217
• 氢给体数：
  7
• 氢受体数：
  8

文献信息

• [EN] AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME<br/>[FR] AGENTS CIBLANT LES AMYLOÏDES ET PROCÉDÉS DE LEUR UTILISATION
  申请人：AMYDIS DIAGNOSTICS

  公开号：WO2015143185A1

  公开（公告）日：2015-09-24

  Provided herein is the design and synthesis of novel molecular rotor fluorophores useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amyloid or amyloid like proteins as compared to unbound compound. Also disclosed herein are the methods for treating of diseases associated with an amyloid or amyloid like proteins.

  本文提供了用于检测淀粉样蛋白或类淀粉样蛋白的新型分子转子荧光团的设计和合成。这些荧光团被设计为与淀粉样蛋白或类淀粉样蛋白结合时，与未结合化合物相比表现出增强的荧光发射。本文还披露了用于治疗与淀粉样蛋白或类淀粉样蛋白相关疾病的方法。
• NOVEL SMALL MOLECULE DNAK INHIBITORS
  申请人：Sturgess Michael Alan

  公开号：US20100087466A1

  公开（公告）日：2010-04-08

  Methods of inhibiting HSP70 proteins, agents causing the inhibition of HSP70 proteins, and the effects of such inhibition on cell proliferation. Anti-microbial agents comprising small molecules, or pharmaceutical salts thereof, disclosed herein and further methods of use thereof are also disclosed. The disclosed small molecules, or pharmaceutical salts thereof, are effective in inhibiting microbial chaperone activity in microbes, such as homologs of HSP70. The disclosed small molecules, or pharmaceutical salts thereof, are also effective for the therapeutic treatment of cancer.

  抑制HSP70蛋白的方法，导致抑制HSP70蛋白的药剂，以及这种抑制对细胞增殖的影响。本文还披露了包含小分子或其药用盐的抗微生物药剂，以及其进一步的使用方法。所披露的小分子或其药用盐对微生物中的分子伴侣活性具有抑制作用，例如HSP70同源物。所披露的小分子或其药用盐还对癌症的治疗治疗有效。
• [EN] ANTIMICROBIAL COMPOUNDS, THEIR SYNTHESIS AND APPLICATIONS THEREOF<br/>[FR] COMPOSÉS ANTIMICROBIENS, LEUR SYNTHÈSE ET LEURS APPLICATIONS
  申请人：JNCASR BANGALORE

  公开号：WO2014097178A1

  公开（公告）日：2014-06-26

  The present disclosure relates to the field of medicinal chemistry and more particularly to the development of antimicrobial compounds. The disclosure relates to the synthesis and characterization of compounds comprising aromatic radical or an aliphatic radical, an alkyl amine and amino acid moiety wherein said compounds exhibit antimicrobial activity against various drug-sensitive and drug-resistant pathogenic 10 microorganisms.

  本公开涉及药物化学领域，更具体地涉及抗菌化合物的开发。该公开涉及合成和表征包含芳香基团或脂肪基团、烷基胺和氨基酸基团的化合物，其中这些化合物对各种对药物敏感和耐药病原微生物表现出抗菌活性。
• [EN] TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS<br/>[FR] ADMINISTRATION CIBLÉE D'INHIBITEURS DE LA VOIE DE RÉCUPÉRATION DE NICOTINAMIDE ADÉNINE DINUCLÉOTIDE
  申请人：SEATTLE GENETICS INC

  公开号：WO2018075600A1

  公开（公告）日：2018-04-26

  Compounds and compositions are disclosed in which a NAMPT Drug Unit is linked to a targeting Ligand Unit through a Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.

  本发明揭示了一种将NAMPT药物单元与靶向配体单元通过一个单元连接的化合物和组合物，其中NAMPT抑制剂化合物或其衍生物在靶向作用位点释放。本发明还揭示了利用这些化合物和组合物治疗由靶向异常细胞特征的疾病的方法，如癌症或自身免疫疾病。
• Chloroquine combination drugs and methods for their synthesis
  申请人：Kosak M. Kenneth

  公开号：US20070060499A1

  公开（公告）日：2007-03-15

  This invention discloses compositions of chloroquine-coupled active agents, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the active agent is delivered, thereby reducing the overall dosage needed. The compositions comprise a chloroquine substance coupled to an active agent directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing active agents for therapeutic or other medical uses. The invention also discloses carrier compositions that are coupled to targeting molecules for targeting the delivery of chloroquine substances and active agents to their site of action.

  这项发明揭示了氯喹偶联活性药剂的组合物，包括其制备方法。先前的技术已经表明，以足够高浓度给予氯喹作为游离药物，可以增强细胞内体内各种药剂从细胞内体释放到细胞质中。这些组合物的目的是在传递活性药剂的相同部位提供受控量的氯喹，从而减少所需的总剂量。这些组合物包括将氯喹物质直接或通过各种药用载体物质偶联到活性药剂。载体物质包括多糖、合成聚合物、蛋白质、胶束和其他用于在体内携带和释放氯喹组合物以产生治疗效果的物质。这些组合物还可以包括用于携带和释放活性药剂以用于治疗或其他医疗用途的生物可降解连接。该发明还揭示了与靶向分子偶联的载体组合物，用于将氯喹物质和活性药剂定位传递到它们的作用部位。